Safety of infliximab in real clinical practice-Reference-Cited by-同舟云学术

Safety of infliximab in real clinical practice

Published:2019-11-26 Issue:18 Volume:1 Page:39-43
ISSN:2078-5631
Container-title:Medical alphabet
language:
Short-container-title:Medicinskij alfavit

Author:

Aronova E. S.¹,Lukina G. V.²

Affiliation:

1. V.A. Nasonova Research Institute of Rheumatology

2. V.A. Nasonova Research Institute of Rheumatology; A. S. Loginov Moscow Clinical Scientific Center

Abstract

A wide range of highly effective genetically engineered biological preparations introduced into clinical rheumatology in recent years causes a special interest in their safety.Purpose of the study. Evaluation of the safety of infliximab therapy in patients with rheumatoid arthritis.Materials and methods. The authors' own data, which analyzed the undesirable effects of infliximab in 135 patients with rheumatoid arthritis in actual clinical practice, are presented. A case report of the adverse reaction of combination therapy with leflunomide and infliximab is presented.Results and its discussion. The overall tolerability of infliximab was satisfactory. Adverse events were observed in 28.1 % of cases, including 19.1 % of patients (14.1 %) had serious side effects that required discontinuation of the drug.Findings. In most cases, infliximab is safe for use in actual clinical practice. Patients should be informed about the risks of undesirable effects and the need for a rheumatologist's examination before each infliximab administration before prescribing therapy.

Publisher

Alfmed LLC

Subject

Materials Chemistry,Economics and Econometrics,Media Technology,Forestry

Reference27 articles.

1. Lukina G. V., Sigidin Ya. A., Chichasova N. V., Balabanova R. M., Belen'kii A. G. i soavt. Primenenie monoklonal'nykh antitel k faktoru nekroza opukholi (Remikeid) pri revmatoidnom artrite: predvaritel'nye rezul'taty. Ter. arkhiv, 2003, T. 75, № 5, S. 9–12.

2. Cozzani E, Larosa M, Parodi A. Skin manifestations associated with anti TNF-α therapy. Clinical Dermatology. 2013 April-June; 2 (2): 67–71. ISSN: 2282–4103.

3. Collamer AN, Battafarano DF. Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis. Semin Arthritis Rheum. 2010 Jun 25. [Epub ahead of print]

4. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009 Nov; 102 (11): 1133–40.

5. Lodhi RL, Shubhini AS, Gaurav K et al. Pharmacology and toxicology of leflunomide. Iranian Journal of Pharmacology and Therapeutist. Jan. 2012, Vol. 11, No. 1, 26–32.